mRNA vaccine development and manufacturing solutions from ProBio

mRNA Vaccine Solutions

As mRNA vaccines advance into infectious disease, oncology, and personalized medicine applications, developers need reliable partners to address manufacturing, quality, delivery, and regulatory challenges. ProBio's integrated DNA-to-LNP platform provides end-to-end support, including plasmid DNA production, IVT-mRNA manufacturing, LNP encapsulation, analytical testing, GMP production, and fill-finish services, helping accelerate programs from discovery to the clinic.

mRNA therapeutics are creating new opportunities across vaccines, oncology, and genetic medicine, increasing the need for efficient and scalable manufacturing. ProBio's integrated DNA-to-LNP platform supports every stage of development, from plasmid DNA production to GMP-ready mRNA-LNP products, helping streamline development and accelerate clinical progress.

With proprietary poly(A) control technologies and expertise in mRNA, saRNA, and circRNA platforms, ProBio achieves IVT-mRNA yields of up to 10 g/L and LNP encapsulation efficiencies of up to 99.7%, enabling high-quality RNA production at scale.

mRNA Plasmid Services

Cell-free and tailored solutions for linearized DNA manufacturing for DNA production.

Learn More

mRNA-LNP Manufacturing

Robust mRNA manufacturing platform supporting diverse RNA lengths, formats, and functionalities from preclinical development through commercial production.

Learn More

One-Stop Solution for RNA-tLNP

End‑to‑end solution from plasmids and linear DNA to IVT RNA, antibodies, LNP encapsulation, and final RNA‑tLNPs, streamlining workflows and reducing time, cost, and complexity.

Learn More

mRNA-LNP IND-Enabling CMC

Seamless, end‑to‑end workflow ensures high‑quality outputs and faster timelines, enabling IND submissions across multiple regulatory agencies.

Learn More

End-to-End Support for mRNA and mRNA-LNP Development

Accelerating mRNA Vaccines with ProBio

Integrated mRNA-LNP manufacturing workflow from DNA to clinic

Integrated DNA-to-LNP Platform

Seamless end-to-end workflow spanning plasmid DNA, IVT-mRNA production, LNP formulation, analytical testing, and GMP manufacturing. Powered by proprietary poly(A)-optimized plasmid, backbone, and strain technologies, ProBio has supported 30+ INDs and 2 BLA programs, helping advance high-quality RNA therapeutics.

Proprietary mRNA and LNP technology platforms for high-yield production

High-Yield RNA Manufacturing Across Diverse Payloads

Advance vaccine and therapeutic programs with flexible mRNA, saRNA, and circRNA platforms supported by high-performance IVT-mRNA production. ProBio delivers IVT-mRNA yields up to 10 g/L and recovery rates up to 80%, enabling efficient development of conventional vaccines and next-generation RNA medicines.

Scalable mRNA vaccine GMP manufacturing with global supply security

Advanced LNP Delivery Platform

Optimize in vivo delivery with diverse LNP formulations and ionizable lipid libraries, delivering up to 99.7% encapsulation efficiency. Experienced in supporting diverse payloads, with 4 IND clearances and over 10 mRNA CMC projects.